Parkinson’s Disease (PD) is a progressive disorder characterized by motor impairments. Cognitive impairment (CI) in people with PD (PwPD) causes “invisible” disability, which can develop independently. Multiple treatment options exist for motor impairment, assessed through interviews, neurological exams, and rating scales (UPDRS). Quality of Life (QoL) can be adversely impacted by psychosocial functioning or daily activity impairments, which are not routinely assessed. The SCOPA-PS PRO assesses psychosocial functioning, the UEFFM-ADL-SF PRO evaluates activities of daily living (ADL), and the LB-IADL PRO measures independent living skills. The relationship between CI to these PROs in PwPD has not been fully explored with computerized cognitive testing (CCT). CCT can enhance routine exams to assess cognitive changes and identify PwPD at risk who might need targeted interventions. Improved awareness and timely targeted treatment could enhance care, satisfaction, and outcomes.

A retrospective cross-sectional analysis of cognitive scores was performed in PwPD who completed a standardized validated CCT (Neurotrax) and PROs. A single-factor ANOVA analysis was performed between the PROs and a global cognitive summary score.

Cognitive function in PwPD is related to psychosocial functioning, motor skills for daily activities, and activities of daily living. CI in PwPD can adversely impact these areas, affecting QoL regardless of clinician awareness. Improved clinician recognition of these invisible problems can lead to earlier interventions and better outcomes. Routine monitoring of cognitive function should be part of standard care for PwPD. Incorporating CCT into routine care can enhance awareness of CI in PwPD.